idea 1,661 words KG: ent-gene-9f063e98 2026-03-24
kind:ideakind:therapy-ideasection:ideasstate:published
Contents

LRRK2 Inhibitor Therapy

🔬 Protein Info
Gene Symbolent-gene-9f063e98
Primary TargetLRRK2 kinase domain (ATP-binding site)
ModalitySmall-molecule kinase inhibitor (ATP-competitive)
IndicationParkinson's disease (LRRK2-associated and sporadic)
Patient SelectionLRRK2 mutation carriers (G2019S, R1441C/G, I2020T) and sporadic PD with elevated LRRK2 activity
KG Connections2 knowledge graph edges
DatabasesGeneCardsUniProtNCBI GeneHPASTRING

Knowledge Graph

Related Hypotheses (24)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
PARP1 Inhibition Therapy
Score: 0.58

Related Analyses (17)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived

Related Experiments (24)

AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40

Knowledge Graph (2 edges)

ent-gene-9f063e98 data_in benchmark_ot_ad_answer_key:LRRK2
benchmark_ot_ad_answer_key:LRRK2 data_in ent-gene-9f063e98